News Release

Printer Friendly Version View printer-friendly version
« Back
Zogenix to Participate in Oppenheimer Life Sciences Summit 2016

EMERYVILLE, Calif., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Gail Farfel, Ph.D., Chief Development Officer, will participate in the Oppenheimer Life Sciences Summit 2016, being held at the Sofitel New York Hotel on Tuesday, November 29th.

About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.

For more information, visit www.zogenix.com.

 

CONTACT:
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com

Primary Logo

Zogenix, Inc.